Effect of nuclear factor kappa B inhibition on L-NAME-induced hypertension and cardiovascular remodelling

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Vrankova, Stanislava ^a   Parohova, Jana ^a   Barta, Andrej ^a   Janega, Pavol ^b   Simko, Fedor ^b   Pechanova, Olga ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

endothelial nitric oxide synthase; fibrosis; hypertrophy; nitric oxide; nuclear factor kappa B

Indexed keywords

ALKADIENE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART WEIGHT; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 77957266973     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388494.58707.0f     Document Type: Article

References (25)

1. Baldwin AS Jr. Series introduction: the transcription factor NF-kB and human disease. J Clin Invest 2001; 107:3-6.
2. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002; 109 (Suppl.):S81-S96.
3. Sekiguchi K, Li X, Coker M, Flesch M, Barger PM, Sivasubramanian N, Mann DL. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004; 63:433-442.
4. Bar-Shai M, Carmeli E, Ljubuncic P, Reznick AZ. Exercise and immobilization in aging animals: the involvement of oxidative stress and NFkappa B activation. Free Radic Biol Med 2008; 44:202-214.
5. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415:206-212.
6. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-kB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105:509-515.
7. Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor kappa B is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 2002; 159:1019-1028.
8. De Keulenaer GW, Wang Y, Feng Y, Muangman S, Yamamoto K, Thompson JF, et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-kB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002; 90:690-696.
9. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995; 96:2521-2527.
10. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 2010; 28:527-535.
11. Collins T. Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68:499-508.
12. Grumbach IM, Chen W, Mertens SA, Harrison DG. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005; 39:595-603.
13. Pechánová O, Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 2009; 27 (Suppl. 6):S32-S36.
14. Pechánová O, Berná tová I, Pelouch V, Simko F. Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29:3365-3374.
15. Pechánová O, Zicha J, Kojsová S, Dobesová Z, Jendeková L, Kunes J. Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension. Clin Sci 2006; 110:235-242.
16. Dolber PC, Spach MS. Conventional and confocal fluorescence microscopy of collagen fibers in the heart. J Histochem Cytochem 1993; 41:465-469.
17. Bernátová I, Kopincová J, Pú zserová A, Janega P, Babá l P. Chronic low-dose L-NAME treatment increases nitric oxide production and vasorelaxation in normotensive rats. Physiol Res 2007; 56 (Suppl. 2):S17-S24.
18. Kojsová S, Jendeková L, Zicha J, Kunes J, Andriantsitohaina R, Pechánová O. The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res 2006; 55 (Suppl. 1):S3-S16.
19. Vranková S, Barta A, Parohová J, Pechánová O. Could NF-kappa B play a role in blood pressure regulation? Focused on L-NAME-induced hypertension. J Hypertens 2009; 27 (Suppl. 4):S140.
20. Madonna R, Massaro M, De Caterina R. Insulin potentiates cytokineinduced VCAM-1 expression in human endothelial cells. Biochim Biophys Acta 2008; 1782:511-516.
21. Lee MH, Hyun DH, Jenner P, Halliwell B. Effect of proteasome inhibition on cellular oxi-dative damage, antioxidant defences and nitric oxide production. J Neurochem 2001; 78:32-41. (Pubitemid 32622586)
22. Sasazuki T, Okazaki T, Tada K, Sakon-Komazawa S, Katano M, Tanaka M, et al. Genomewide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol Immunol 2004; 41:547-551.
23. Pereira LM, Mandarim-De-Lacerda CA. Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition. Pathol Res Pract 1999; 195:177-181.
24. Kitamoto S, Egashira K, Kataoka C, Koyanagi M, Katoh M, Shimokawa H, et al. Increased activity of nuclear factor-kappa B participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation 2000; 102:806-812.
25. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The subendothelial extracellular matrix modulates NF-kappa B activation by flow: a potential role in atherosclerosis. J Cell Biol 2005; 169:191-202.